Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy

Abstract

Purpose

The aim of this study was to determine whether the outcome to neoadjuvant chemotherapy (NAC) can be predicted by analyzing p53 expression in hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients.

Methods

We retrospectively reviewed 594 patients diagnosed with stage I–III HR-positive, HER2-negative breast cancer, and treated with NAC at the Asan Medical Center between 2008 and 2014. Expression of p53 was assessed, and overall survival (OS) and breast cancer-specific survival (BCSS) were investigated and compared between groups.

Results

At a median follow-up period of 69.8 months, OS and BCSS were higher in the p53-negative (p53(−)) group than in the p53-positive (p53(+)) group. Five-year OS was 95.4% in the p53(−) and 92.1% in the p53(+) group (p = 0.005). BCSS was 96.2% in the p53(−) group and 93% in the p53(+) group (p = 0.008).

Conclusion

High expression of immunohistochemically detected p53 was strongly and significantly associated with decreased OS and BCSS than low p53 expression, suggesting that p53 may be a powerful prognostic factor in HR-positive, HER2-negative breast cancer patients receiving NAC.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References:

  1. 1.

    Beslija S et al (2009) Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 20(11):1771–1785. https://doi.org/10.1093/annonc/mdp261

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Schettini F, Buono G, Cardalesi C, Desideri I, De Placido S, Del Mastro L (2016) Hormone receptor/human epidermal growth factor receptor 2-positive breast cancer: where we are now and where we are going. Cancer Treat Rev 46:20–26. https://doi.org/10.1016/j.ctrv.2016.03.012

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Abe O et al (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451–1467. https://doi.org/10.1016/S0140-6736(97)11423-4

    Article  Google Scholar 

  4. 4.

    Boughey JC et al (2014) Tumor biology correlates with rates of breastconserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer findings from the ACOSOG Z1071 (alliance) prospective multicenter clinical trial. Ann Surg 260(4):608–616. https://doi.org/10.1097/SLA.0000000000000924

    Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    von Minckwitz G et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796–1804. https://doi.org/10.1200/JCO.2011.38.8595

    Article  Google Scholar 

  6. 6.

    Cortazar P et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet (London, England) 384(9938):164–172. https://doi.org/10.1016/S0140-6736(13)62422-8

    Article  Google Scholar 

  7. 7.

    Koboldt DC et al (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70. https://doi.org/10.1038/nature11412

    CAS  Article  Google Scholar 

  8. 8.

    Rossner P Jr et al (2009) Mutations in p53, p53 protein overexpression and breast cancer survival. J Cell Mol Med 13(9b):3847–3857. https://doi.org/10.1111/j.1582-4934.2008.00553.x

    Article  PubMed  Google Scholar 

  9. 9.

    Bertheau P et al (2002) Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 360(9336):852–854. https://doi.org/10.1016/S0140-6736(02)09969-5

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Elledge RM, Allred DC (1998) Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 52(1–3):79–98. https://doi.org/10.1023/a:1006163101948

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Olivier M et al (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12(4):1157–1167. https://doi.org/10.1158/1078-0432.CCR-05-1029

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Basho RK et al (2016) Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget 7(47):76362–76373. https://doi.org/10.18632/oncotarget.12987

    Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Cianfrocca M, Goldstein LJ (2004) Prognostic and predictive factors in early-stage breast cancer. Oncologist 9(6):606–616. https://doi.org/10.1634/theoncologist.9-6-606

    Article  PubMed  Google Scholar 

  14. 14.

    Nicolini A, Carpi A, Tarro G (2006) Biomolecular markers of breast cancer. Front Biosci 11:1818–1843. https://doi.org/10.2741/1926

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Abubakar M et al (2019) Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression. npj Breast Cancer 5(1):20. https://doi.org/10.1038/s41523-019-0117-7

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Bouchalova P et al (2014) Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status. J Pathol 233(3):238–246. https://doi.org/10.1002/path.4356

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Barbareschi M (1996) Progn. value immunohistochem. expr. p53 breast carcinomas a rev. lit. involv. over 9,000 patients. 4(2):106–116 (1996)

  18. 18.

    Mirza AN, Mirza NQ, Vlastos G, Singletary SE (2002) Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 235:1

    Article  Google Scholar 

  19. 19.

    Bae SY, Lee JH, Bae JW, Jung SP (2020) Differences in prognosis by p53 expression after neoadjuvant chemotherapy in triple-negative breast cancer. Ann Surg Treat Res 98(6):291–298. https://doi.org/10.4174/astr.2020.98.6.291

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported by the Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea (Grant Number 2020-0037).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Sae Byul Lee.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Albinsaad, L.S., Kim, J., Chung, I.Y. et al. Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy. Breast Cancer Res Treat (2021). https://doi.org/10.1007/s10549-021-06134-6

Download citation

Keywords

  • Immunohistochemistry
  • Neoadjuvant therapy
  • Prognosis
  • Breast neoplasms
  • Tumor suppressor protein p53